Uncovering the cathepsin system in heart failure patients submitted to Left Ventricular Assist Device (LVAD) implantation

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  D'Amico, Andrea ^a   Ragusa, Rosetta ^b   Caruso, Raffaele ^c   Prescimone, Tommaso ^b   Nonini, Sandra ^d   Cabiati, Manuela ^b   Del Ry, Silvia ^b   Trivella, Maria Giovanna ^b   Giannessi, Daniela ^b   Caselli, Chiara ^b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c CNR   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiac remodeling; Cathepsin system; Heart failure; LVAD therapy

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN G; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CYSTATIN B; CYSTATIN C; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SERPIN A3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; INTENSIVE CARE; LEFT VENTRICULAR ASSIST DEVICE; LENGTH OF STAY; MALE; PROGNOSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; HEART ASSIST DEVICE; HEART VENTRICLE; METABOLISM; PATHOPHYSIOLOGY;

CATHEPSINS; FEMALE; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; MALE;

EID: 84924801144     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0350-7     Document Type: Article

References (41)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, et al: Heart Disease and Stroke Statistics-2014 Update: a report from the American heart association. Circulation 2014, 129(3):e28-e292.
2. Wilson SR, Givertz MM, Stewart GC, Mudge GH Jr: Ventricular assist devices the challenges of outpatient management. J Am Coll Cardiol 2009, 54(18):1647-1659.
3. Hall JL, Fermin DR, Birks EJ, Barton PJ, Slaughter M, Eckman P, Baba HA, Wohlschlaeger J, Miller LW: Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol 2011, 57(6):641-652.
4. Muller AL, Dhalla NS: Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 2012, 17(3):395-409.
5. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T: Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012, 125(12):1551-1562.
6. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D: Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 2012, 1824(1):68-88.
7. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S: Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007, 21:3029-3041.
8. Taglieri N, Koenig W, Kaski JC: Cystatin C and cardiovascular risk. Clin Chem 2009, 55(11):1932-1943.
9. Turk B, Turk D, Salvesen GS: Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des 2002, 8:1623-1637.
10. Korkmaz B, Moreau T, Gauthier F: Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 2008, 90(2):227-242.
11. Horvath AJ, Irving JA, Rossjohn J, Law RH, Bottomley SP, Quinsey NS, Pike RN, Coughlin PB, Whisstock JC: The murine orthologue of human antichymotrypsin. A structural paradigm for clade A3 serpins. J Biol Chem 2005, 280(52):43168-43178.
12. Wågsäter D, Johansson D, Fontaine V, Vorkapic E, Bäcklund A, Razuvaev A, Mäyränpää MI, Hjerpe C, Caidahl K, Hamsten A, Franco-Cereceda A, Wilbertz J, Swedenborg J, Zhou X, Eriksson P: Serine protease inhibitor A3 in atherosclerosis and aneurysm disease. Int J Mol Med 2012, 30(2):288-294.
13. Tan GJ, Peng ZK, Lu JP, Tang FQ: Cathepsins mediate tumor metastasis. World J Biol Chem 2013, 4(4):91-101.
14. Chwieralski CE, Welte T, Bühling F: Cathepsin-regulated apoptosis. Apoptosis 2006, 11:143-149.
15. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaka T, Saka M, Kimata T, Noda A, Nagata K, Jin H, Shi GP, Iguchi A, Murohara T, Yokota M: Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006, 48:979-987.
16. Li X, Liu Z, Cheng Z, Cheng X: Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease. Chonnam Med J 2012, 48(2):77-85.
17. Reiser J, Adair B, Reinheckel T: Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010, 120:3421-3431.
18. Hua Y, Xu X, Shi GP, Chicco AJ, Ren J, Nair S: Cathepsin K knockout alleviates pressue overload-induced cardiac hypertrophy. Hypertension 2013, 61:1184-1192.
19. Arnlöv J: Cathepsin S as a biomarker: where are we now and what are the future challenges? Biomark Med 2012, 6(1):9-11.
20. Caselli C, D'Amico A, Caruso R, Cabiati M, Prescimone T, Cozzi L, Cannata A, Parodi O, Del Ry S, Giannessi D: Impact of normalization strategy on cardiac expression of pro-inflammatory cytokines: Evaluation of reference genes in different human myocardial regions after Left Ventricular Assist Device support. Cytokine 2013, 63(2):113-122.
21. Pätilä T, Kukkonen S, Vento A, Pettilä V, Suojaranta-Ylinen R: Relation of the Sequential Organ Failure Assessment score to morbidity and mortality after cardiac surgery. Ann Thorac Surg 2006, 82:2072-2078.
22. Caruso R, Verde A, Cabiati M, Milazzo F, Boroni C, Del Ry S, Parolini M, Vittori C, Paino R, Martinelli L, Giannessi D, Frigerio M, Parodi O: Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients. J Heart Lung Transplant 2012, 31:625-633.
23. Bustin SA: Why the need for qPCR publication guidelines?-the case for MIQE. Methods 2010, 50(4):217-226.
24. Caselli C, D'Amico A, Ragusa R, Caruso R, Prescimone T, Cabiati M, Nonini S, Marraccini P, Del Ry S, Trivella MG, Parodi O, Giannessi D: IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediators Inflamm 2013, 2013:498703.
25. Cheng XW, Kuzuya M, Sasaki T, Arakawa K, Kanda S, Sumi D, Koike T, Maeda K, Tamaya-Mori N, Shi GP, Saito N, Iguchi A: Increased expression of elastolytic cysteine proteases, cathepsin S and K, in the neointima of ballon-injured rat carotid arteries. Am J Pathol 2004, 164:243-251.
26. Jiang H, Cheng XW, Shi GP, Hu L, Inoue A, Yamamura Y, Wu H, Takeshita K, Li X, Huang Z, Song H, Asai M, Hao CN, Unno K, Koike T, Oshida Y, Okumura K, Murohara T, Kuzuya M: Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia. Nat Commun 2014, 5:3838.
27. Hu L, Cheng XW, Song H, Inoue A, Jiang H, Li X, Shi GP, Kozawa E, Okumura K, Kuzuya M: Cathepsin K activity controls injury-related vascular repair in mice. Hypertension 2014, 63(3):607-615.
28. Jahanyar J, Youker KA, Loebe M, Assad-Kottner C, Koerner MM, Torre-Amione G, Noon GP: Mast cell-derived cathepsin G: a possible role in the adverse remodeling of the failing human heart. J Surg Res 2007, 140(2):199-203.
29. Rafiq K, Hanscom M, Valerie K, Steinberg SF, Sabri A: Novel mode for neutrophil protease cathepsin G-mediated signaling: membrane shedding of epidermal growth factor is required for cardiomyocyte anoikis. Circ Res 2008, 102(1):32-41.
30. Xu JM, Shi GP: Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev 2012, 33(1):71-108.
31. Shiota N, Rysa J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA: A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003, 21:1935.
32. Lu H, Meléndez GC, Levick SP, Janicki JS: Prevention of adverse cardiac remodeling to volume overload in female rats is the result of an estrogen-altered mast cell phenotype. Am J Physiol Heart Circ Physiol 2012, 302(3):H811-H817.
33. Palaniyandi SS, Inagaki K, Mochly-Rosen D: Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure. J Mol Cell Cardiol 2008, 45(6):779-786.
34. Jiang B, Liao R: The paradoxical role of inflammation in cardiac repair and regeneration. J Cardiovasc Transl Res 2010, 3:410-416.
35. Petermann I, Mayer C, Stypmann J, Biniossek ML, Tobin DJ, Engelen MA, Dandekar T, Grune T, Schild L, Peters C, Reinheckel T: Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J 2006, 20:1266-1268.
36. Sun M, Chen M, Liu Y, Fukuoka M, Zhou K, Li G, Dawood F, Gramolini A, Liu PP: Cathepsin-L contributes to cardiac repair and remodelling post-infarction. Cardiovasc Res 2010, 89:374-383.
37. Bengtsson E, To F, Håkansson K, Grubb A, Brånén L, Nilsson J, Jovinge S: Lack of cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscl Thromb Vasc Biol 2005, 25:2151-2156.
38. Butler CR, Jugdutt BI: The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly. Heart Fail Rev 2012, 17(4-5):615-633.
39. Caruso R, Botta L, Verde A, Milazzo F, Vecchi I, Trivella MG, Martinelli L, Paino R, Frigerio M, Parodi O: Relationship between pre-implant interleukin-6 levels, inflammatory response, and early outcome in patients supported by left ventricular assist device: a prospective study. PLoS One 2014, 9(3):e90802.
40. Qin YW, Ye P, He JQ, Sheng L, Wang LY, Du J: Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR β and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin 2010, 31(10):1350-1358.
41. Cheng XW, Kuzuya M, Sasaki T, Inoue A, Hu L, Song H, Huang Z, Li P, Takeshita K, Hirashiki A, Sato K, Shi GP, Okumura K, Murohara T: Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens 2011, 29(3):542-552.